Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib has been accepted for review by China’s National Medical Products Administration (NMPA). Zetomipzomib is a first-in-class selective immunoproteasome inhibitor currently under development for a variety of autoimmune diseases, including lupus nephritis and systemic lupus erythematosus (SLE).
In September, Everest Medicines entered into a cooperation and licensing agreement with Kezar Life Sciences, securing development and commercialization rights for zetomipzomib in Greater China, South Korea, and select Southeast Asian countries for a total consideration exceeding USD 130 million. Previous clinical trials have demonstrated that zetomipzomib exhibits favorable safety and tolerability profiles in treating severe and chronic autoimmune conditions. The drug is currently being evaluated in the global Phase IIb PALIZADE study focused on active lupus nephritis.- Flcube.com
